Novel methylation gene panel in adjacent normal tissues predicts poor prognosis of colorectal cancer in Taiwan

Table 1 Characteristics and distribution of methylation status in patients with colorectal cancer (n = 120), n (%)

Variables	Total	Methylation status
		OAF		≥ 3 of genes1
		Normal	Tumors	Normal	Tumors
Sex
Male	60 (50.0)	13 (28.9)	28 (62.2)	16 (26.7)	41 (68.3)
Female	60 (50.0)	16 (34.8)	34 (73.9)	19 (31.7)	41 (68.3)
Age in yr at surgery
Mean (SD)	63.8 (14.8)	62.6 (12.6)	63.2 (15.0)	62.5 (13.5)	62.5 (15.3)
< 65	61 (50.8)	15 (30.0)	33 (66.0)	19 (31.1)	45 (73.8)
≥ 65	59 (49.2)	14 (34.1)	29 (70.7)	16 (27.1)	37 (62.7)
Stage
	19 (15.8)	2 (16.7)	6 (50.0)	6 (31.6)	10 (52.6)
	39 (32.5)	6 (20.7)	22 (75.9)	11 (28.2)	26 (66.7)
	40 (33.3)	14 (45.2)	22 (71.0)	11 (27.5)	29 (72.5)
	22 (18.3)	7 (36.8)	12 (63.2)	7 (31.8)	17 (77.3)
Adjuvant chemotherapy
No	32 (28.3)	5 (22.7)	13 (59.1)	13 (40.6)	23 (71.9)
Yes	81 (71.7)	24 (36.9)	46 (70.8)	22 (27.2)	55 (67.9)
Lymph/vascular invasion
No	44 (97.8)	12 (35.3)	21 (61.8)	18 (40.9)	28 (63.6)
Yes	1 (2.2)	0 (0)	1 (100.0)	0 (0)	1 (100.0)
Histological grade2
Well or Moderately	96 (88.9)	23 (31.9)	45 (62.5)	31 (32.3)	62 (64.6)
Poor or undifferentiated	12 (11.1)	5 (45.5)	10 (90.9)	2 (16.7)	11 (91.7)
Tumor location2
Colon	89 (78.8)	19 (28.4)	46 (68.7)	27 (30.3)	59 (66.3)
Rectum	24 (21.2)	10 (50.0)	13 (65.0)	8 (33.3)	19 (79.2)
Progression in 5 yr
No	75 (62.5)	11 (22.0)a	33 (66.0)	17 (22.7)a	46 (61.3)
Yes	45 (37.5)	18 (43.9)	29 (70.7)	18 (40.0)	36 (80.0)
All-cause death in 5 yr
No	97 (80.8)	22 (31.0)	50 (70.4)	28 (28.9)	67 (69.1)
Yes	23 (19.2)	7 (35.0)	12 (60.0)	7 (30.4)	15 (65.2)

¹Including CDKN2A, hMLH1, MGMT, CSF2, DIS3L2, and OAF.

²The total number of patients with colorectal cancer does not correspond because of missing data.

^aP < 0.05. OAF: The out at first homolog gene; SD: Standard deviation.